Schizophrenia Trial of Aripiprazole

Otsuka

Status and phase: Completed; Phase 3

Conditions: Schizophrenia

Treatments: Drug: Aripiprazole; Drug: Olanzapine or Quetiapine or Risperidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00237913

CN138-152

Details and patient eligibility

About

Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of schizophrenia
• Schizophrenia symptoms not optimally controlled or antipsychotic medication not well tolerated

Exclusion criteria

• Diagnosis of schizoaffective disorder
• Patients treatment-resistant to antipsychotics

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

700 participants in 2 patient groups

A1

Active Comparator group

Treatment:

Drug: Aripiprazole

B1

Active Comparator group

Treatment:

Drug: Olanzapine or Quetiapine or Risperidone